Page URL:

Second IVF company to be floated sees share prices grow

30 June 2014
Appeared in BioNews 760

An Australian fertility company has seen the price of its shares rise on the first day of its public listing on the stock market.

Shares in the Monash IVF Group rose 6.5 percent after opening at AU$1.96, meaning the country's second largest IVF company grew by almost AU$13 million in value in one day on its debut to the market.

The company is the second public listing from the Australian fertility sector in the last year to enter the stock market and follows the public listing of Virtus, the world's first listed fertility company.

Monash IVF boasts three of the top fertility specialists and hosts clinics in the Australian states of Victoria, South Australia and the Northern Territory. The company provides genetic testing and ultrasounds, as well fertility services, which make up the majority of its earnings.

Monash expanded to Malaysia in 2013 and has co-operative clinics in China. On Tuesday, chief executive, James Thiedeman, told Business Day: 'Our focus will remain on building our footprint in Malaysia and looking to expand our service across the broader Association of Southeast Asian Nations region'.

Other health related companies are following suit. Pacific Equity Partners listed hygiene products company Asaleo Care Ltd on Friday and has so far raised AU$656 million in shares. Reuters explains there is opportunity for investors to benefit from the growing demand of a health system in Australia that is heavily subsidised by the state.

Another IVF provider joins share market
The West Australian |  26 June 2014
Australia's Monash IVF shares jump on debut after raising $297 mln
Reuters |  25 June 2014
Healthy start for Monash IVF baby
The Australian |  26 June 2014
Monash IVF makes solid ASX debut
Sydney Morning Herald |  26 June 2014
29 August 2017 - by Shaoni Bhattacharya 
Treatment costs for IVF may be coming down in Australia as a result of a price war between fertility clinics...
21 November 2016 - by Rikita Patel 
A number of Australian IVF clinics are potentially misleading patients about their success rates, a consumer watchdog has warned...
23 June 2014 - by Dr Anna Cauldwell 
Two patients with the serious inherited blood disorder beta-thalassemia have been able to stop blood transfusions 12 days after receiving experimental gene therapy...
17 March 2014 - by Patricia Cassidy 
Myriad Genetics has failed to obtain a preliminary injunction to prevent a competitor, Ambry Genetics, from offering BRCA-related genetic testing products...
17 June 2013 - by Jessica Ware 
The first IVF business to be listed on the stock market enjoyed a buoyant first day of trading on the Australian exchange. Shares in Virtus Health closed 8.5 percent above their starting price, which was already set at the top end of an indicative range...
31 January 2012 - by Ruth Saunders 
Swiss pharmaceutical company Roche has made an unsolicited bid worth $5.7 billion to takeover US DNA sequencing firm Illumina....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.